The purpose of HTA is to provide high-quality information to decision makers about the clinical effectiveness, cost-effectiveness, and broader impact of drugs, medical technologies, and health systems.
Biosimilar medicines are follow-on versions of original biological medicines.
HTA should be based on an in-depth interaction to discuss specific data required in order to deci
HTAs should be a flexible process used collaboratively. The use of HTA to make reimbursement dec
A disease is defined as rare in Europe when it affects less than 1 in 2,000 citizens (Orphan Drug